Authors
Latest:
Seeing Through Physicians' Eyes: Three Priorities for PharmaPhysicians who show true empathy for their patients tend to have better outcomes. Their patients stick to treatment plans, heal faster, and have fewer hospital readmissions. The same principle applies to pharma companies trying to market to physicians, write Pratap Khedkar and Malcolm Sturgis.
Latest:
The Healing Art in MedicinePharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.
Latest:
From 1990s Business Wisdom to Today’s BioPharma SuccessApplying the McKinsey 7S Framework to TLL and regional marketing teams.
Latest:
Marketing Curative Therapies: Are We Ready?The eight trends brought on by “once-and-done” interventions that may transform thinking around healthcare marketing.
Latest:
Emergency Disaster Response: Three Ways Pharmas Can HelpAs vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.
Latest:
The Creative Impulse: Defending Pharma and Health DTCDefending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
Latest:
Sales & Marketing: Reaching the UnreachablesThe traditional commercial sales model in biopharma of deploying teams of reps to call on physicians is broken. Here, Stephen J. Donnelly outlines a new approach.
Latest:
Navigating Success During a Rare Disease Product LaunchWebinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST
Latest:
How One Pollster Correctly Predicted BrexitOnly one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.
Latest:
The True Nature of Danger Behind IP Waiver ProposalIssue represents a potential threat in fighting future pandemics.
Latest:
Commercial Models for a New Healthcare EcosystemCompanies must design local commercial models that enable them to deliver value stories tailored to the specific needs of organized customers and the characteristics of local ecosystems, writes Paul Darling.
Latest:
Branding: When One is Not EnoughThe power of a second brand in the evolving global healthcare market, write Ram Subramanian and Dr. Rehan Baqri.
Latest:
Pharma dot-gov: A New Business ModelAn advocate of business system automation in the global pharma supply chain offers a six-pronged approach to adapting to the realities of a new age of mounting regulation and customer expectations.
Latest:
Eight Tips on Improving KOL EngagementGary Kaplan offers surveying tips to help identify both tactical and strategic initiatives required for a true key performance indicator.
Latest:
Supply Chain Integration or Bust… or BothThe recent formation of three mega supply-chain purchasing groups (Walgreen’s-AllianceBoots-AmerisourceBergen-Rite-Aid, McKesson-Celesio, CVS-Cardinal) denotes a shift in the balance of power between wholesalers, chains, generic pharmaceutical companies and branded pharma companies.
Latest:
Private Payers in Canada Embrace Product Listing AgreementsArvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.
Latest:
The Digital Healthcare EvolutionBruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.
Latest:
What “Precision Medicine” Means for Rare DiseasesPresident Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman.
Latest:
What Errors Do We Miss in Clinical Trials?As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development.
Latest:
Beyond 2020: Building Strategic Coherence in the New Health EconomyPositioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Latest:
Beyond 2020: Building Strategic Coherence in the New Health EconomyPositioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Latest:
The Great Life Sciences Regulatory RedressElvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.
Latest:
March 2017: Big Data, Big Opportunity in Life SciencesThe big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
